Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma -

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Information type: Other primary research
Source: Journal of Clinical Oncology
Specialities: Cancers | Skin disorders
Summary
This analysis of pooled data from 10 prospective and two retrospective studies of ipilimumab found that it was associated with a median overall survival of 11.4 months. When data from an expanded access program were included, the median OS was 9.5 months.
UKMi comment
NICE recommends ipilimumab as an option for treating advanced (unresectable or metastatic) melanoma in people who have received prior therapy (TA268; December 2012), and in those who have not received any previous treatment (TA319; July 2014), as long as the manufacturer provides it with the discount agreed in the patient access scheme.
Related links: NICE guidance (TA268)NICE guidance (TA319)